{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:47:38Z","timestamp":1793839658542,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF\\u20102019R1A2C3008992"],"award-info":[{"award-number":["NRF\\u20102019R1A2C3008992"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A2C3008992"],"award-info":[{"award-number":["2019R1A2C3008992"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI19C0753"],"award-info":[{"award-number":["HI19C0753"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.biomaterials.2021.121209","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T15:10:22Z","timestamp":1634829022000},"page":"121209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["White adipocyte-targeted dual gene silencing of FABP4\/5 for anti-obesity, anti-inflammation and reversal of insulin resistance: Efficacy and comparison of administration routes"],"prefix":"10.1016","volume":"279","author":[{"given":"Jee Young","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-9789","authenticated-orcid":false,"given":"Juhyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonsung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Beom","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-507X","authenticated-orcid":false,"given":"Yong-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biomaterials.2021.121209_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.biomaterials.2021.121209_bib2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bluher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"11","key":"10.1016\/j.biomaterials.2021.121209_bib3","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCRESAHA.115.306885","article-title":"Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease","volume":"118","author":"Fuster","year":"2016","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121209_bib4","doi-asserted-by":"crossref","first-page":"17034","DOI":"10.1038\/nrdp.2017.34","volume":"3","author":"Gonz\u00e1lez-Muniesa","year":"2017","journal-title":"Obesity, Nature Reviews Disease Primers"},{"issue":"8","key":"10.1016\/j.biomaterials.2021.121209_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrendo.2014.94","article-title":"Obesity and cancer--mechanisms underlying tumour progression and recurrence","volume":"10","author":"Park","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.biomaterials.2021.121209_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41574-018-0126-x","article-title":"The obese adipose tissue microenvironment in cancer development and progression","volume":"15","author":"Quail","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.biomaterials.2021.121209_bib7","first-page":"817","article-title":"Obesity management: update on orlistat","volume":"3","author":"Drew","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.biomaterials.2021.121209_bib8","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S58459","article-title":"Liraglutide and obesity: a review of the data so far","volume":"9","author":"Ladenheim","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/j.biomaterials.2021.121209_bib9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ncpendmet0563","article-title":"Surgical treatment of obesity","volume":"3","author":"Kral","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metabol."},{"issue":"7121","key":"10.1016\/j.biomaterials.2021.121209_bib10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biomaterials.2021.121209_bib11","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic inflammation and insulin resistance in obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.biomaterials.2021.121209_bib12","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.biomaterials.2021.121209_bib13","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1530\/JOE-16-0211","article-title":"Adipose tissue in control of metabolism","volume":"231","author":"Luo","year":"2016","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.biomaterials.2021.121209_bib14","first-page":"1216783","article-title":"Differential role of adipose tissues in obesity and related metabolic and vascular complications","volume":"2016","author":"Gomez-Hernandez","year":"2016","journal-title":"Internet J. Endocrinol."},{"issue":"8","key":"10.1016\/j.biomaterials.2021.121209_bib15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.arcmed.2008.09.005","article-title":"White adipose tissue as endocrine organ and its role in obesity","volume":"39","author":"V\u00e1zquez-Vela","year":"2008","journal-title":"Arch. Med. Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121209_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrendo.2016.136","article-title":"Brown adipose tissue as a secretory organ","volume":"13","author":"Villarroya","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"10.1016\/j.biomaterials.2021.121209_bib17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nmat4092","article-title":"Oligopeptide complex for targeted non-viral gene delivery to adipocytes","volume":"13","author":"Won","year":"2014","journal-title":"Nat. Mater."},{"issue":"20","key":"10.1016\/j.biomaterials.2021.121209_bib18","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1073\/pnas.1603840113","article-title":"Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles","volume":"113","author":"Xue","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.biomaterials.2021.121209_bib19","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/db11-0194","article-title":"Inflammation is necessary for long-term but not short-term high-fat diet\u2013induced insulin resistance","volume":"60","author":"Lee","year":"2011","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.biomaterials.2021.121209_bib20","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.biomaterials.2021.121209_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4103\/ijem.IJEM_206_18","article-title":"Evaluation of proinflammatory cytokines in obese vs non-obese patients with metabolic syndrome","volume":"22","author":"Ashraf","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121209_bib22","doi-asserted-by":"crossref","first-page":"16364","DOI":"10.1038\/s41598-020-73347-y","article-title":"Elevated adipose tissue associated IL-2 expression in obesity correlates with metabolic inflammation and insulin resistance","volume":"10","author":"Kochumon","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biomaterials.2021.121209_bib23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2021.121209_bib24","doi-asserted-by":"crossref","DOI":"10.4093\/dmj.2019.0221","article-title":"Serum levels of adipocyte fatty acid-binding protein are associated with rapid renal function decline in patients with type 2 diabetes mellitus and preserved renal function","author":"Seo","year":"2020","journal-title":"Diabetes Metab. J"},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121209_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210932","article-title":"Correction: serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, A clinical study","volume":"14","author":"Nakamura","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biomaterials.2021.121209_bib26","article-title":"Cardiomyocyte overexpression of FABP4 aggravates pressure overload-induced heart hypertrophy","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2021.121209_bib27","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.atherosclerosis.2018.06.181","article-title":"Fatty acid binding protein 4 (FABP4) contributes to myocardial steatosis and insulin resistance in cardiac cells","volume":"275","author":"Rodriguez-Calvo","year":"2018","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.biomaterials.2021.121209_bib28","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/ATVBAHA.115.305365","article-title":"Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals","volume":"35","author":"Reiser","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.biomaterials.2021.121209_bib29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/ATVBAHA.116.307225","article-title":"Local production of fatty acid-binding protein 4 in epicardial\/perivascular fat and macrophages is linked to coronary atherosclerosis","volume":"36","author":"Furuhashi","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biomaterials.2021.121209_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1475-2840-11-72","article-title":"Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells","volume":"11","author":"Aragones","year":"2012","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.biomaterials.2021.121209_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179737","article-title":"Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, A clinical study","volume":"12","author":"Nakamura","year":"2017","journal-title":"PLoS One"},{"issue":"319","key":"10.1016\/j.biomaterials.2021.121209_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac6336","article-title":"Development of a therapeutic monoclonal antibody that targets secreted fatty acid\u2013binding protein aP2 to treat type 2 diabetes","volume":"7","author":"Burak","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2021.121209_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10059-011-0026-6","article-title":"Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic analysis of cytosolic and secreted proteins","volume":"31","author":"Hwang","year":"2011","journal-title":"Mol. Cell."},{"issue":"12","key":"10.1016\/j.biomaterials.2021.121209_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167825","article-title":"Transcriptome and metabolome analyses in exogenous FABP4- and FABP5-treated adipose-derived stem cells","volume":"11","author":"Yamamoto","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.biomaterials.2021.121209_bib35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.amjcard.2010.06.028","article-title":"Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus","volume":"106","author":"Bagheri","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.biomaterials.2021.121209_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081318","article-title":"Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population","volume":"8","author":"Ishimura","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biomaterials.2021.121209_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cmet.2004.12.008","article-title":"Adipocyte\/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes","volume":"1","author":"Maeda","year":"2005","journal-title":"Cell Metabol."},{"issue":"2","key":"10.1016\/j.biomaterials.2021.121209_bib38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/diabetes.52.2.300","article-title":"Role of the fatty acid binding protein mal 1 in obesity and insulin resistance","volume":"52","author":"Maeda","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.biomaterials.2021.121209_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.09.023","article-title":"Visceral adipose tissue macrophage-targeted TACE silencing to treat obesity-induced type 2 diabetes","volume":"148","author":"Yong","year":"2017","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.biomaterials.2021.121209_bib40","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1101\/gr.246900.118","article-title":"Targeted delivery of CRISPR interference system against Fabp4 to white adipocytes ameliorates obesity, inflammation, hepatic steatosis and insulin resistance","volume":"29","author":"Chung","year":"2019","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.biomaterials.2021.121209_bib41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molmed.2005.02.004","article-title":"Prohibitin: a potential target for new therapeutics","volume":"11","author":"Mishra","year":"2005","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2021.121209_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121209_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes Sci Pract"},{"issue":"7","key":"10.1016\/j.biomaterials.2021.121209_bib44","first-page":"687","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015"},{"issue":"2","key":"10.1016\/j.biomaterials.2021.121209_bib45","first-page":"194","article-title":"Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats","volume":"33","author":"Hansen","year":"2012"},{"issue":"6651","key":"10.1016\/j.biomaterials.2021.121209_bib46","first-page":"610","article-title":"Protection from obesity-induced insulin resistance in mice lacking TNF-\u03b1 function","volume":"389","author":"Uysal","year":"1997"},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121209_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41387-020-0114-9","article-title":"Reducing endogenous insulin is linked with protection against hepatic steatosis in mice","volume":"10","author":"Akheruzzaman","year":"2020","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.biomaterials.2021.121209_bib48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DMSO.S146339","article-title":"Obesity and nonalcoholic fatty liver disease: current perspectives","volume":"11","author":"Sarwar","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.biomaterials.2021.121209_bib49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2017.08.035","article-title":"Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes","volume":"268","author":"Nurunnabi","year":"2017","journal-title":"J. Contr. Release"},{"issue":"9","key":"10.1016\/j.biomaterials.2021.121209_bib50","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1021\/acsnano.8b04315","article-title":"Oral nanoparticles exhibit specific high-efficiency intestinal uptake and lymphatic transport","volume":"12","author":"Kim","year":"2018","journal-title":"ACS Nano"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221005664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221005664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:02:46Z","timestamp":1777485766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961221005664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":50,"alternative-id":["S0142961221005664"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121209","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"White adipocyte-targeted dual gene silencing of FABP4\/5 for anti-obesity, anti-inflammation and reversal of insulin resistance: Efficacy and comparison of administration routes","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121209"}}